O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+55.65%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$6.98B
AUM Growth
+$6.98B
(+34%)
Cap. Flow
+$27.1M
Cap. Flow
% of AUM
0.39%
Top 10 Holdings %
Top 10 Hldgs %
37.73%
Holding
152
New
37
Increased
17
Reduced
34
Closed
13
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$109M |
| 2 |
89bio
ETNB
|
$105M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$104M |
| 4 |
Danaher
DHR
|
$98.1M |
| 5 |
Glaukos
GKOS
|
$84.3M |
Top Sells
| 1 |
AVDR
Avedro, Inc Common Stock
AVDR
|
$96.3M |
| 2 |
WMGI
Wright Medical Group Inc
WMGI
|
$79.2M |
| 3 |
Neurocrine Biosciences
NBIX
|
$68.7M |
| 4 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$58.9M |
| 5 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
$56.6M |
Sector Composition
| 1 | Healthcare | 98.02% |
| 2 | Financials | 1.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Danaher
DHR
$143B
| $98.1M | 1.4% |
+638,900
| New | +$98.1M |
|
27
Bausch Health
BHC
$2.72B
| $95.2M | 1.36% |
3,183,100
-129,200
| -4% | -$3.87M |
|
|
DCPH
28
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $94.2M | 1.35% |
1,514,171
-946,400
| -38% | -$58.9M |
|
|
29
Glaukos
GKOS
$5.42B
| $84.3M | 1.2% |
+1,547,646
| New | +$84.3M |
|
30
PTC Therapeutics
PTCT
$4.41B
| $83.1M | 1.19% |
1,729,200
-229,700
| -12% | -$11M |
|
31
Natera
NTRA
$23B
| $82.2M | 1.17% |
2,440,613
-559,515
| -19% | -$18.9M |
|
32
Regeneron Pharmaceuticals
REGN
$59.8B
| $78.6M | 1.12% |
209,300
-18,800
| -8% | -$7.06M |
|
33
Arvinas
ARVN
$580M
| $78M | 1.11% |
1,898,800
-196,483
| -9% | -$8.07M |
|
34
uniQure
QURE
$954M
| $77.5M | 1.11% |
1,081,765
+242,165
| +29% | +$17.4M |
|
35
Thermo Fisher Scientific
TMO
$183B
| $71.6M | 1.02% |
220,500
-131,400
| -37% | -$42.7M |
|
36
MeiraGTx Holdings
MGTX
$590M
| $69.1M | 0.99% |
3,453,020
+103,960
| +3% | +$2.08M |
|
37
Tandem Diabetes Care
TNDM
$834M
| $68M | 0.97% |
1,141,390
+477,000
| +72% | +$28.4M |
|
38
Exelixis
EXEL
$9.95B
| $66.1M | 0.94% |
3,753,700
-159,200
| -4% | -$2.81M |
|
39
Abbott
ABT
$230B
| $62.1M | 0.89% |
715,100
-107,300
| -13% | -$9.32M |
|
|
HZNP
40
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $57.3M | 0.82% |
+1,582,300
| New | +$57.3M |
|
41
Krystal Biotech
KRYS
$4.35B
| $55.1M | 0.79% |
994,808
+392,858
| +65% | +$21.8M |
|
|
BLU
42
DELISTED
BELLUS Health Inc.
BLU
| $53.1M | 0.76% |
7,025,832
| – | – |
|
43
DexCom
DXCM
$30.9B
| $51.4M | 0.73% |
234,900
-149,100
| -39% | -$32.6M |
|
44
Crinetics Pharmaceuticals
CRNX
$3.26B
| $51.2M | 0.73% |
2,039,282
| – | – |
|
45
Adverum Biotechnologies
ADVM
$68.2M
| $50M | 0.71% |
4,342,190
+329,221
| +8% | +$3.79M |
|
46
Aurinia Pharmaceuticals
AUPH
$1.58B
| $47.5M | 0.68% |
2,345,447
-1,185,555
| -34% | -$24M |
|
47
CRISPR Therapeutics
CRSP
$4.82B
| $46.7M | 0.67% |
766,378
+249,978
| +48% | +$15.2M |
|
|
LOGC
48
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
| $46.6M | 0.66% |
6,466,783
| – | – |
|
49
Prothena Corp
PRTA
$452M
| $45.9M | 0.66% |
2,902,239
-119,878
| -4% | -$1.9M |
|
|
ATNX
50
DELISTED
Athenex, Inc. Common Stock
ATNX
| $42.3M | 0.6% |
2,772,221
-536,699
| -16% | -$8.2M |
|